Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha
about
Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDsRheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters FunctionDeterminants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Effect of noncompetitive proteasome inhibition on bortezomib resistance.Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probeTargeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Interaction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiologyAbatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistanceABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides.Drug transport by breast cancer resistance protein.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Treat-to-target: a tailored treatment approach to rheumatoid arthritis.Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner.Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis.Acquired resistance of human T cells to sulfasalazine.Multidrug transporter activity in lymphocytes.Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.Iron metabolism and drug resistance in cancer.Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1).
P2860
Q28394186-0C3FC9F8-19B0-4B1A-9264-9682B87AAC3AQ28552801-22EFFA00-96D2-4659-891D-F95A66EDE196Q30364846-C06C0563-993D-491F-B0DA-A1D6541543EDQ33588424-33BC296A-DD63-4E05-A627-538A82013240Q33704930-D4EE25B3-C6F9-4F77-A422-BD950E0AC05CQ33763765-DAA269FB-0C1A-4635-A61A-C7428AA93938Q33985206-AFC872C1-F3BB-420A-93C3-9EC397BC0AADQ34871636-DB5646C7-E541-4BB0-A6A3-2056B6FC29CDQ34968909-F53E6B67-93B6-413D-8485-D244FEEA7339Q35637221-2C04F760-3B85-46A6-A08A-3201E879EEA2Q35912731-2A177F97-2A4E-4758-B6BA-D414FBCE4D94Q36245600-5339FA37-4432-4B24-96D3-A1AAE2C2292BQ37032656-7AA6078A-E4A8-4085-928A-C88AE4665F4CQ37478653-340F8970-5E7A-4654-924E-763250F2D4D0Q37595188-081977F1-39D2-4DDA-B994-9F1EC5087149Q37726997-40B2A877-86DC-4C25-BF71-CBA52CE2C366Q37793056-5DA861E5-999C-4F3F-A3C5-8D431661404BQ37958162-C171859A-0E78-4C68-8385-E239FDB88A09Q38071700-1B5F6918-8212-4BD4-8EF2-CB3064A0A33DQ38125456-9131A1F4-7ECE-4C03-8BDD-E49F3E673969Q39316019-0F7E51D4-804E-4AC7-846B-726A4E2B37C7Q40176569-EBE84F16-14A2-42D6-9B04-EE0A68DBA1C6Q42966692-BC0590AF-7C27-4B1A-8707-FD3FDA747F3BQ43141327-59F18FA9-A261-42CE-85DD-E28405893CDBQ47803536-E84EB533-BE7B-4777-806F-AC0FB90A4D23Q48001406-43ADF9B7-2A0B-4463-8A82-0014A2DF1378Q52576052-D0D82512-C1D4-4DD9-A05D-694CDC4683BA
P2860
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Development of sulfasalazine r ...... gmented production of TNFalpha
@ast
Development of sulfasalazine r ...... gmented production of TNFalpha
@en
Development of sulfasalazine r ...... gmented production of TNFalpha
@nl
type
label
Development of sulfasalazine r ...... gmented production of TNFalpha
@ast
Development of sulfasalazine r ...... gmented production of TNFalpha
@en
Development of sulfasalazine r ...... gmented production of TNFalpha
@nl
prefLabel
Development of sulfasalazine r ...... gmented production of TNFalpha
@ast
Development of sulfasalazine r ...... gmented production of TNFalpha
@en
Development of sulfasalazine r ...... gmented production of TNFalpha
@nl
P2093
P2860
P3181
P356
P1476
Development of sulfasalazine r ...... gmented production of TNFalpha
@en
P2093
B A C Dijkmans
C G Schalkwijk
G L Scheffer
I Kathmann
J van der Heijden
M C de Jong
R J Scheper
R Oerlemans
P2860
P304
P3181
P356
10.1136/ARD.2002.005249
P407
P577
2004-02-01T00:00:00Z